In high Tuberculosis (TB) burden countries, the doctors are often forced to start empirical antibiotic treatment without proper diagnosis, due to very limited or unavailability of proficient diagnostic tests. Consumption of empirical antibiotics helps the bacteria to develop multidrug resistance (MDR) and initiates severe life-long side effects in the patient. This leads to extra suffering for patients treated with unnecessary antibiotics, further spread of TB and MDR-TB in the community, and socio-economic burden. Therefore, WHO insists on the need for rapid molecular tests that can provide confirmatory information especially at decentralized and primary health care levels or medical camps, where scarcity of resources leads to development of drug resistance. EMPE provides diagnostic test kits in this segment facilitating efficient treatment at the first contact with clinician bringing down the treatment initiation time from months to 120 minutes.


EMPE’s products are inexpensive, easy-to-use, molecular tests that rapidly provide reliable answers about the bacteria and its resistance genotypic results. Our multiplex nucleic acid tests can detect the bacteria and their genotypic resistance results by developing a visual signal. Clinicians can get confirmatory results in a ‘YES’ or ‘NO’ format, within 2 h. As a result, doctors will be able to select the appropriate drugs enabling effective antibiotic treatment and limit transmission of MDR-TB.


EMPE Diagnostics’ tests combine molecular tools called padlock probes with lateral flow biosensor to identify the bacteria and its antibiotic resistance in a fast and accurate manner. Such a novel combination enables highly specific identification of multiple segments and/or positions in TB DNA and provide the results in less than 2h, in a convenient and easy to interpret PRESENCE/ABSENCE format by developing visual signals. Our patented technology offers confirmatory detection of nucleic acids by providing highly sensitive visual signals,even in resource-limited clinical laboratories across the world.

Inexpensive, easy-to-use, multiplex molecular tests that provide results in 2 h


Tuberculosis (TB) is a contagious disease caused by a type of bacteria called Mycobacterium tuberculosis, which grows very slowly inside the lungs. Therefore, it is hard to detect until the bacteria have multiplied enough to show typical TB symptoms. TB is curable, if it is detected in early stages and treated with necessary and correct antibiotics. However, TB is often associated with HIV and diabetes putting the patient’s life at higher risk.

About 1.7 billion people are infected worldwide, and 10 million fall ill (show symptoms) every year where Bangladesh, China, India, Indonesia, Nigeria, Pakistan and Philippines top the rank. TB kills 1.6 million people every year where about 95% of TB deaths occur in Low-/Middle Income Countries (LMICs). Despite TB being curable, the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) is an increasing global health concern. Global TB report 2018 estimates that 3.5% of the new cases and 18% of relapse cases are DR-TB. The WHO region of Europe which includes all of former Soviet Union accounts for around 40% of MDR-TB cases. The majority of drug-resistant cases (MDR/XDR-TB) have been reported in India, China and Russia.

Among the 10 million active TB patients, there are around 500 000 people living with MDR/XDR-TB, who can potentially spread the resistant bacteria in the society, simply by coughing. According to the end TB, more than 40% of people with TB are missed, almost 80% with drug-resistant (DR-TB) are missed. Even though more than USD 9 billion is being spent on TB, at least 3 million TB cases are not detected and only 1 in 4 patients get MDR-TB treatment. Quick and correct diagnosis is therefore of the uttermost importance.